Instil Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TIL research report →
Range $2 – $120
Price Chart
About the company
Instil Bio, Inc. , a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need.
- CEO
- Bronson Crouch
- IPO
- 2021
- Employees
- 17
- HQ
- Dallas, TX, US
Get TickerSpark's AI analysis on TIL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $46.69M
- P/E
- -1.54
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.43
- EV/EBITDA
- -1.51
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -26.78%
- ROIC
- -18.61%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-534,000+0.0%
- Op Income
- $-52,907,000
- Net Income
- $-71,372,000+3.7%
- EPS
- $-10.70+6.1%
- OCF Growth
- +34.3%
- FCF Growth
- +44.3%
- 52W High
- $21.98
- 52W Low
- $5.67
- 50D MA
- $7.36
- 200D MA
- $8.01
- Beta
- 1.94
- RSI (14)
- 36
- Avg Volume
- 11.78K
No earnings-call transcripts are available for TIL yet.
- Free Float
- 53.4%
- Shares Outstanding
- 6.78M
- Float Shares
- 3.62M
of shares held by institutions
31 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bml Capital Management, LLC | 645.60K | 0 |
| Cpmg Inc | 410.92K | 0 |
| Vivo Capital, LLC | 292.74K | 0 |
| Vanguard Group Inc | 191.06K | ▲ 23.25K |
| Ubs Group AG | 177.42K | ▲ 171.04K |
| Vanguard Capital Management LLC | 163.74K | ▼ 10.85K |
| Millennium Management LLC | 134.57K | ▲ 1.63K |
| Kalehua Capital Management LLC | 99.60K | ▼ 83.43K |
| Blackrock, Inc. | 55.50K | ▲ 3.49K |
| Renaissance Technologies LLC | 50.30K | ▼ 8.80K |
| Macquarie Management Holdings, Inc. | 50.00K | 0 |
| Jacobs Levy Equity Management, Inc | 43.05K | ▲ 43.05K |
Held by 32 ETFs
Biggest fund positions in TIL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 26 | McGaughy R Kent Jr | other | 6,500 |
| Jun 11, 26 | Matcham George | other | 6,500 |
| Jun 11, 26 | Gibson Neil W | other | 0 |
| Jun 11, 26 | Binder Gwendolyn | other | 6,500 |
| Sep 10, 25 | Laumas Sandeep | other | 13,000 |
| Sep 10, 25 | Laumas Sandeep | other | 13,000 |
| Sep 10, 25 | Laumas Sandeep | other | 17,000 |
| Sep 10, 25 | Laumas Sandeep | other | 17,000 |
| Sep 10, 25 | Laumas Sandeep | sell | 17,539 |
| Sep 10, 25 | Laumas Sandeep | sell | 12,461 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TIL coverage
Recent articles, reports, and earnings notes.
No research on TIL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TIL report →Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
gurufocus.com · Oct 2
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
marketbeat.com · Sep 19
5 Biotech Stocks Worth Adding to Your Portfolio Now
zacks.com · Aug 26
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 13
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
gurufocus.com · Aug 3
Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)
seekingalpha.com · Jul 16
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
globenewswire.com · Jun 1
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · May 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.